Stifel Nicolaus Boosts uniQure (NASDAQ:QURE) Price Target to $32.00

uniQure (NASDAQ:QURE) had its price target increased by investment analysts at Stifel Nicolaus from $12.00 to $32.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Stifel Nicolaus’ price target points to a potential upside of 94.41% from the company’s previous close.

QURE has been the subject of a number of other research reports. Royal Bank of Canada raised their target price on shares of uniQure from $14.00 to $20.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. The Goldman Sachs Group boosted their target price on shares of uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, December 12th. Leerink Partners raised their target price on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. Cantor Fitzgerald lifted their price objective on uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday, December 10th. Finally, Raymond James raised uniQure from an “outperform” rating to a “strong-buy” rating and increased their target price for the stock from $20.00 to $52.00 in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.13.

uniQure Stock Performance

QURE opened at $16.46 on Monday. The firm has a market capitalization of $802.31 million, a PE ratio of -3.27 and a beta of 0.89. uniQure has a 52-week low of $3.73 and a 52-week high of $17.71. The business’s 50-day simple moving average is $7.28 and its 200 day simple moving average is $6.47. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. The company had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. As a group, sell-side analysts expect that uniQure will post -3.82 earnings per share for the current fiscal year.

Insider Transactions at uniQure

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the sale, the chief executive officer now owns 597,915 shares in the company, valued at $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.74% of the stock is currently owned by corporate insiders.

Institutional Trading of uniQure

Hedge funds and other institutional investors have recently bought and sold shares of the business. RTW Investments LP bought a new position in uniQure in the 3rd quarter valued at about $49,000. China Universal Asset Management Co. Ltd. boosted its holdings in uniQure by 57.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 3,663 shares during the last quarter. Atria Investments Inc bought a new position in shares of uniQure in the third quarter valued at approximately $53,000. Quarry LP purchased a new position in shares of uniQure in the 3rd quarter worth about $58,000. Finally, Vanguard Personalized Indexing Management LLC lifted its stake in uniQure by 21.0% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 2,306 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.